Aligos Therapeutics Inc (ALGS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$6.21-0.16%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ALGS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -18.6% |
| Our one-year growth estimate | diamond | -10.4% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 8.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ALGS — litigation filed
Dated 2026-04-21
Entry into a Material Definitive Agreement. On April 16, 2026, Aligos Therapeutics, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Xiamen Amoytop Biotech Co., Ltd. (“Amoytop”), pursuant to which the Company grants to Amoytop an exclusive, non-transferable, royalty-bearing license, under certain Company-controlled intellectual property, to manufacture, develop and commercialize the Company’s investigational compound pevifoscorvir sodium in its current dosa…
Why it matters: Progress on ALG-170675 could show growth in Aligos's treatments for chronic HBV.
Supportive ifAligos gives a good update on ALG-170675's IND-enabling studies.
Worry ifThere are no updates or bad news about ALG-170675's progress.
Why it matters: Exceeding this revenue would show strong clinical and commercial progress. It would confirm the growth trajectory.
Supportive ifQ2 revenue was over $2.83M. This shows continued growth.
Worry ifQ2 revenue reported below $2.83M, suggesting a slowdown in growth.
Why it matters: This payment indicates progress in the development of ALG-170675. It helps fund Aligos' operations.
Supportive ifAligos gets a $3M payment from Amoytop for ALG-170675's IND approval.
Worry ifThe milestone payment is delayed or not received as expected.
Why it matters: Advancements in this drug could drive revenue and investor interest. It's key for growth.
Supportive ifLook for news about good trial results. Also, watch for partnerships for pevifoscorvir sodium.
Worry ifThere are no updates or bad news about pevifoscorvir sodium.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$321 on $10,000 · ±3.2% | How much price usually moves either way. |
| Bad day | $844 loss on $10,000 · 8.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,931 loss on $10,000 · 69.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The results will show if the study continues to meet its goals for HBV treatment.
Supportive ifThe second interim analysis shows good results for the main goal of the study.
Worry ifThe second interim analysis shows that the study does not meet the main goal.
Why it matters: Lawsuit results can change partnerships and future earnings. This is important for investors.
Worry ifLook for news about a settlement that helps Aligos.
Less concerning ifWatch for bad rulings or lawsuits that are still going on.
Why it matters: Progress on this drug could strengthen Aligos' position in the HBV treatment market.
Supportive ifUpdates show that the ASO is moving well through IND-enabling studies.
Worry ifThere are no updates or delays in the ASO's progress through IND-enabling studies.
Why it matters: Completing enrollment is crucial for timely data release. It shows the study is on track.
Supportive ifThe HBeAg- group now has 100 participants as the DSMB suggested.
Worry ifEnrollment does not reach the target of 100 participants by the end of 2026.
Why it matters: Updates on cash position will show if Aligos can fund operations through late 2026. This affects their development plans.
Worry ifCash and cash equivalents are over $30M. This shows enough funding.
Less concerning ifCash and cash equivalents fall below $20M, raising concerns about funding.
Why it matters: Finishing enrollment is an important step in clinical trials. It can change when data comes out and affect future funding.
Supportive ifEnrollment has reached the goal of 245 participants as planned.
Worry ifEnrollment fails to reach the targeted number or delays occur.
Why it matters: This payment reflects progress in the development of ALG-170675 and supports Aligos' cash position. It is crucial for funding ongoing operations.
Supportive ifThe $3M milestone payment is received as expected.
Worry ifThe payment is delayed or not received.
Why it matters: Management needs to keep cash reserves for ongoing operations. Signs of cash issues could hurt future projects.
Worry ifManagement says they have enough cash to run operations until late 2026.
Less concerning ifManagement says cash reserves are not enough or plans to raise more money.
Why it matters: Topline data will show how well pevifoscorvir sodium works for chronic HBV. Good results could make investors more confident and help the company's growth.
Supportive ifTopline data shows big improvement in HBV markers compared to the control group.
Worry ifTopline data shows no big difference or bad results compared to the control group.